Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Standard-dose vs Intermediate-dose Cytarabine Induction in AML With RUNX1-RUNX1T1
NCT06744504Phase 3Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jan 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cytarabine in acute myeloid leukemia (AML), sponsored by Institute of Hematology and Blood Diseases Hospital. Started Jan 2025; status: recruiting.
02
Drugs
cytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06744504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06744504.